ArticleKidney international reports2026
Systematic Review of Kidney Involvement in Antisynthetase Syndrome.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Antisynthetase syndrome (ASyS) is a rare autoimmune disorder characterized by autoantibodies targeting aminoacyl-tRNA synthetases. Kidney involvement has been historically regarded as uncommon and remains poorly characterized. Methods: We conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines (PROSPERO: CRD420261282317). MEDLINE, Scopus, Web of Science, and Google Scholar were searched from inception to January 2026. We included adults with biopsy-proven or clinically defined kidney involvement in ASyS. Risk of bias was assessed using Joanna Briggs Institute tools; certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation framework. Results: Thirty-eight articles comprising 52 patients were included. Kidney disease presented with or following interstitial lung disease (ILD) in 81% of cases. Among 35 biopsied patients, membranous nephropathy (29%), pauci-immune crescentic glomerulonephritis (23%), acute tubular necrosis (17%), and tubulointerstitial nephritis (11%) were identified. Non-Jo1 antibodies predominated in vasculitic phenotypes and were associated with higher peak creatinine than anti-Jo1 (4.7 vs. 2.3 mg/dl; Conclusion: Kidney involvement in ASyS carries substantial clinical significance. Non-Jo1 serotype may predict worse kidney outcomes, though this association requires confirmation in prospective cohorts with multivariable adjustment. Routine kidney surveillance and early antibody-guided immunosuppression may improve outcomes, pending validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.